ArticleBMC cardiovascular disorders2026
Association between platelet/high-density lipoprotein cholesterol ratio and incidence of coronary heart disease: insights from the UK Biobank.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe platelet-to-high-density lipoprotein cholesterol ratio (PHR) integrates platelet count and HDL-C concentration and may reflect thrombo-inflammatory and lipid-related cardiovascular risk. However, its association with incident coronary heart disease (CHD) and its incremental value beyond its individual components remain uncertain.
methodsWe included 326,803 UK Biobank participants without baseline CHD. PHR was calculated as platelet count (×10
resultsDuring a median follow-up of 13.0 years, 20,340 incident CHD events occurred. Compared with participants in the lowest PHR quartile, those in the highest quartile had a higher hazard of incident CHD in the fully adjusted model (HR 1.36, 95% CI 1.31-1.42; P < 0.01). The association was also observed for CHD subtypes and appeared stronger for AMI (Q4 vs. Q1: HR 1.68, 95% CI 1.56-1.81) than for chronic ischemic heart disease (Q4 vs. Q1: HR 1.38, 95% CI 1.32-1.45). Restricted cubic spline analysis suggested a non-linear association between log-transformed PHR and incident CHD (P for non-linearity < 0.001), with a relatively flat association at lower values and a steeper increase at higher values. PHR showed moderate discrimination for incident CHD (AUC 0.716, 95% CI 0.713-0.720), and adding PHR to the fully adjusted clinical model produced a small increase in C-index (0.714 to 0.720), larger than that observed when platelet count or HDL-C was added separately. Exploratory analyses suggested that hs-CRP, HbA1c, and neutrophil count statistically accounted for part of the observed association, although these findings may reflect shared inflammatory and metabolic background rather than causal mediation.
conclusionHigher PHR was associated with increased risk of incident CHD in this large prospective cohort, particularly for AMI. PHR may serve as a simple adjunctive marker for CHD risk stratification when interpreted alongside established clinical risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.